The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Biochemical Pharmacology

• Publication date

  1988-12-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-2952(88)90336-XPMID 3144286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.

  1988cited by this paper
• Rat liver NAD(P)H:quinone reductase: isolation of a quinone reductase structural gene and prediction of the NH2 terminal sequence of the protein by double-stranded sequencing of exons 1 and 2.

  1988cited by this paper
• Rat liver NAD(P)H: quinone reductase nucleotide sequence analysis of a quinone reductase cDNA clone and prediction of the amino acid sequence of the corresponding protein.

  1987cited by this paper
• Antibody directed enzymes revive anti-cancer prodrugs concept.

  1987cited by this paper
• Data for Biochemical Research

  1986cited by this paper
• CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells.

  1986cited by this paper
• Chairman's Summary of Session D

  1986cited by this paper
• Purification and characterization of two isofunctional forms of NAD(P)H: quinone reductase from mouse liver.

  1986cited by this paper
• NAD(P)H:menadione oxidoreductase. Novel purification of enzyme cDNA and complete amino acid sequence, and gene regulation.

  1986cited by this paper
• Hydrolysis of riboflavin nucleotides in plasma monitored by high-performance liquid chromatography.

  1982cited by this paper
• Rat liver cytosolic azoreductase. Electron transport properties and the mechanism of dicumarol inhibition of the purified enzyme.

  1979cited by this paper
• The use of the D-T diaphorase for the detection of foci of early neoplastic transformation in rat liver.

  1978cited by this paper
• The activity of the D-T diaphorase in experimental hepatomas.

  1977cited by this paper
• The activity of the D-T diaphorase in experimental hepatomas.

  1977cited by this paper
• Studies on the protection by imidazoles against the cytotoxicity of the antitumour alkylating agents melphalan and CB 1954.

  1976cited by this paper
• The metabolism of the anti-tumour agent 1(1-aziridinyl)- 2,4-dinitrobenzene (CB 1837).

  1975cited by this paper
• The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates.

  1975cited by this paper
• Studies on the reaction mechanism of DT diaphorase. Action of dead-end inhibitors and effects of phospholipids.

  1975cited by this paper
• Properties and reaction mechanism of DT diaphorase from rat liver.

  1974cited by this paper
• Studies on the reversal of the selective antitumour effect of the aziridinyl derivative cb 1954 by 4‐amino‐5‐imidazolecarboxamide

  1972cited by this paper
• Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. II.

  1971cited by this paper
• The Sensitivity to Chemotherapeutic Agents of a Rat Tumour Grown in Immunosuppressed Mice

  1971cited by this paper
• Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships.

  1969cited by this paper
• Tumour-growth inhibitorynitrofphenylaziridines and related compounds structure-activity relationships

  1969cited by this paper
• 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

  1969cited by this paper
• A spectrophotometric method for the estimation of the carcinostatic agent, 5-aziridino-2,4-dinitrobenzamide (CB 1954), in biological fluids.

  1969cited by this paper
• Intracellular hydrogen transport in Ehrlich ascites tumor cells.

  1967cited by this paper
• The metabolism of 4-nitroquinoline-1-oxide, a carcinogen. 3. An enzyme catalyzing the conversion of 4-nitroquinoline-1-oxide to 4-hydroxyaminoquinoline-1-oxide in rat liver and hepatomas.

  1966cited by this paper
• Soluble Diaphorase in Animal Tissues.

  1958cited by this paper

• A nitroreductase-responsive fluorescence turn-on photosensitizer for lysosomes imaging and photodynamic therapy.

  2024cites this paper
• Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells

  2023cites this paper
• Refined control of CRISPR-Cas9 gene editing in Clostridium sporogenes: the creation of recombinant strains for therapeutic applications

  2023cites this paper
• The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach

  2023cites this paper
• Heterologous Gene Regulation in Clostridia: Rationally Designed Gene Regulation for Industrial and Medical Applications

  2022cites this paper
• The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach

  2021cites this paper
• Enamine N-Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents

  2021cites this paper
• Chemical screening reveals Ronidazole is a superior pro-drug to Metronidazole for Nitroreductase-induced cell ablation system in zebrafish larvae.

  2021cites this paper
• NTR 2.0: a rationally-engineered prodrug converting enzyme with substantially enhanced efficacy for targeted cell ablation

  2021cites this paper
• Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours

  2021cites this paper
• 0 Repurposing 18 F-FMISO as a PET tracer for translational imaging of 1 nitroreductase-based gene directed enzyme prodrug therapy . 2

  2021cites this paper
• Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy

  2021cites this paper
• Prodrugs for nitroreductase based cancer therapy-4: Towards prostate cancer targeting: Synthesis of N-heterocyclic nitro prodrugs, Ssap-NtrB enzymatic activation and anticancer evaluation.

  2020cites this paper
• Evaluation of two xenobiotic reductases from Pseudomonas putida for their suitability for magnetic nanoparticle‐directed enzyme prodrug therapy as a novel approach to cancer treatment

  2020cites this paper
• NTR 2.0: a rationally-engineered prodrug converting enzyme with substantially enhanced efficacy for targeted cell ablation

  2020cites this paper
• NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis

  2020cites this paper
• Time dependent HPLC analysis of the product ratio of enzymatically reduced prodrug CB1954 by a modified and immobilised nitroreductase

  2019cites this paper
• PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.

  2019cites this paper
• Mechanistic Studies on D-arginine Dehydrogenase and Functional Annotation of a Novel NADH:quinone Oxidoreductase (PA1024)

  2018cites this paper
• An improved cell-permeable fluorogenic substrate as the basis for a highly sensitive test for NAD(P)H quinone oxidoreductase 1 (NQO1) in living cells.

  2018cites this paper
• Correction: Ni(II)-Catalyzed enantioselective Mukaiyama–Mannich reaction between silyl enol ethers and cyclic N-sulfonyl α-ketiminoesters

  2017cites this paper
• Stereoselective Synthesis of Fused Aziridines via One-Pot Sequential Decarboxylative Mannich Reaction and Oxidative C-H Amination of Cyclic Imines with β-Ketoacids.

  2016cites this paper
• Metabolic Activation and Drug Targeting

  2016cites this paper
• Functional Annotation of a Presumed Nitronate Monoxygenase Reveals a New Class of NADH:Quinone Reductases*

  2016cites this paper
• Discovery and development of imaging-capable bacterial nitroreductases and their cytotoxic prodrugs for Clostridium sporogenes based gene therapy

  2015influential citation
• Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.

  2015cites this paper
• BASES FOR BREADTH - INSIGHTS INTO HOW THE MECHANISM AND DYNAMICS OF NITROREDUCTASE CAN EXPLAIN THIS ENZYME'S BROAD SUBSTRATE REPERTOIRE

  2014cites this paper
• Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

  2013cites this paper
• Functional Analysis of the Zebrafish Caudal Fin Regeneration

  2013cites this paper
• Modulation of Nitro-fatty Acid Signaling

  2013cites this paper
• Enzyme sensitive synthetic polymer micelles based on the azobenzene motif.

  2013cites this paper
• NITROALKENE REDUCTASE PROSTAGLANDIN REDUCTASE-1 IS A Modulation of Nitro-fatty Acid Signaling: Lipids:

  2013cites this paper
• Development of bacterial nitroreductase enzymes for noninvasive imaging in cancer gene therapy

  2013influential citation
• Topoisomerase-II mediated biochemical mapping of centromeres and nitroreductase mediated drug metabolism in Trypanosomatids

  2012cites this paper
• Targeted Prodrugs of a Novel Platform Anthracycline: Doxazolidine

  2012cites this paper
• An unusually cold active nitroreductase for prodrug activations.

  2012cites this paper
• Investigation of the activation of tumour-specific immune responses by gene therapy strategies using a model tumour antigen

  2012cites this paper
• Targeting hypoxia in cancer therapy

  2011cites this paper
• Enzyme‐Activated Prodrug Strategies for Site‐Selective Drug Delivery

  2011cites this paper
• ROLES OF BIOTRANSFORMATION IN THE ANTITUMOUR ACTIVITY AND TOXICOLOGY OF THE HYPOXIA-ACTIVATED PRE- PRODRUG PR-104

  2010cites this paper
• Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine

  2010cites this paper
• 4 – Chemical Modifiers of Radiation Response

  2010cites this paper
• Fetal genotype for the xenobiotic metabolizing enzyme NQO1 influences intrauterine growth among infants whose mothers smoked during pregnancy.

  2010cites this paper
• Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation.

  2009cites this paper
• Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy

  2009cites this paper
• Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases.

  2008cites this paper
• Structure, function, and mechanism of cytosolic quinone reductases.

  2008cites this paper
• Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.

  2007cites this paper
• Suicide genes for cancer therapy.

  2007cites this paper
• Targeting tumors with hypoxia-activated cytotoxins.

  2007cites this paper
• Tumor hypoxia in cancer therapy.

  2007cites this paper
• Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB 1954 in mouse and rat.

  2007cites this paper
• Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.

  2007cites this paper
• Pro- and antioxidant functions of quinones and quinone reductases in mammalian cells.

  2006cites this paper
• DT-Diaphorase under Aerobic but not Hypoxic Conditions Are Deficient in Chinese Hamster Ovary Cell Lines Resistant to Mitomycin C Updated

  2006cites this paper
• Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo

  2006cites this paper
• Expression in Human Non-Small Cell Lung Carcinoma Cigarette Smoking Is a Determinant of DT-Diaphorase Gene Updated

  2006cites this paper
• Sensor/effector drug design with potential relevance to cancer.

  2006cites this paper
• Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation

  2006cites this paper
• From bench to bedside for gene-directed enzyme prodrug therapy of cancer.

  2005cites this paper
• Aerobic 2- and 4-nitroreduction of CB 1954 by human liver.

  2005cites this paper
• Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex.

  2005cites this paper
• Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954.

  2005cites this paper
• Genetic Prodrug Activation Therapy (GPAT)

  2005cites this paper
• Molecular Chemotherapy Approaches

  2005cites this paper
• Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.

  2004cites this paper
• NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY

  2004cites this paper
• DNA lesions and cytogenetic changes induced by N-nitrosomorpholine in HepG2, V79 and VH10 cells: the protective effects of Vitamins A, C and E.

  2004cites this paper
• 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

  2004cites this paper
• Exploiting tumour hypoxia in cancer treatment

  2004cites this paper
• Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.

  2004cites this paper
• Enzyme-Catalyzed Activation of Anticancer Prodrugs

  2004cites this paper
• Quinone reductase-mediated nitro-reduction: clinical applications.

  2004cites this paper
• CB 1954: from the Walker tumor to NQO2 and VDEPT.

  2003cites this paper
• Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK

  2003cites this paper
• Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.

  2003cites this paper
• Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression.

  2003cites this paper
• Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.

  2003cites this paper
• Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.

  2003cites this paper
• Development of a novel enzyme/prodrug system for hypoxia- and radiation-mediated gene therapy of cancer.

  2002cites this paper
• Clostridium spores for tumor-specific drug delivery.

  2002cites this paper
• CHAPTER 8 – GENE-DIRECTED ENZYME PRODRUG THERAPY

  2002cites this paper
• Feline hyperthyroidism: advances towards novel molecular therapeutics.

  2002cites this paper
• Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954.

  2002cites this paper
• Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

  2002cites this paper
• Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.

  2002cites this paper
• E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.

  2001cites this paper
• Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.

  2001cites this paper
• Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.

  2001cites this paper
• Mechanism of NAD(P)H:Quinone reductase: Ab initio studies of reduced flavin

  2001cites this paper
• Pharmacological aspects of targeting cancer gene therapy to endothelial cells.

  2001cites this paper
• Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy.

  2001cites this paper
• Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives

  2001cites this paper
• The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: Induction of bystander killing in vitro and in vivo

  2000cites this paper
• Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954

  2000cites this paper
• A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C

  2000influential citation
• The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review.

  2000cites this paper
• Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.

  2000cites this paper
• NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.

  2000cites this paper
• Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice

  2000cites this paper